NCT03979352View on ClinicalTrials.gov

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Type1 Diabetes Mellitus
Interventions
DRUG

empagliflozin

Treatment with empagliflozin 25mg orally once a day

DEVICE

artificial pancreas

Insulin delivery via a closed loop single-hormone artificial pancreas system.

Trial Locations (2)

M5T 3L9

Sinai Health System, Toronto

H3A 2B4

McGill University, Montreal

All Listed Sponsors
collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

lead

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

OTHER

NCT03979352 - Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting | Biotech Hunter | Biotech Hunter